Lataa...
Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers
BACKGROUND: Mortalin is enriched in a large variety of cancers and has been shown to contribute to proliferation and migration of cancer cells in multiple ways. It has been shown to bind to p53 protein in cell cytoplasm and nucleus causing inactivation of its tumor suppressor activity in cancer cell...
Tallennettuna:
| Julkaisussa: | J Exp Clin Cancer Res |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6923857/ https://ncbi.nlm.nih.gov/pubmed/31856867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1500-9 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|